Corient Private Wealth LLC Sells 150 Shares of BioNTech SE (NASDAQ:BNTX)

Corient Private Wealth LLC reduced its stake in shares of BioNTech SE (NASDAQ:BNTX) by 7.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,784 shares of the company’s stock after selling 150 shares during the period. Corient Private Wealth LLC’s holdings in BioNTech were worth $203,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its stake in BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. lifted its position in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the last quarter. GAMMA Investing LLC boosted its stake in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after buying an additional 300 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. bought a new position in BioNTech during the fourth quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of BioNTech during the fourth quarter worth approximately $168,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Morgan Stanley lowered their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a research note on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. HC Wainwright decreased their price objective on BioNTech from $150.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Wells Fargo & Company assumed coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. Three analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $143.44.

BioNTech Stock Performance

Shares of BNTX stock opened at $90.29 on Wednesday. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $110.45 and a 200 day moving average of $113.41. The firm has a market capitalization of $21.67 billion, a price-to-earnings ratio of -43.00 and a beta of 0.30. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. BioNTech’s revenue was down 19.5% on a year-over-year basis. As a group, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.